Hydrocortisone administered to extremely preterm infants who remained intubated at 14 to 28 days failed to improve survival without moderate or severe bronchopulmonary dysplasia at 36 weeks’ postmenstrual age compared with placebo.
“In this multicenter, randomized, placebo-controlled trial involving infants at high risk for bronchopulmonary dysplasia, hydrocortisone treatment did not lead to substantially higher survival without moderate or severe bronchopulmonary dysplasia at 36 weeks of postmenstrual age than placebo, nor did hydrocortisone treatment alter the severity of